| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/21/2011 | US7964185 Apicomplex vaccine strains of a family of Sarcocystidae |
| 06/21/2011 | US7963935 Microprojection array having a beneficial agent containing coating |
| 06/21/2011 | CA2492775C Polyalkylene glycol acid additives |
| 06/21/2011 | CA2435681C Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| 06/21/2011 | CA2407556C Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| 06/21/2011 | CA2405290C Vaccine against cancerous diseases |
| 06/21/2011 | CA2386019C Methods related to immunostimulatory nucleic acid-induced interferon |
| 06/21/2011 | CA2370143C Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/21/2011 | CA2299442C Catalytic monoclonal antibodies with protease activity for the selective lysis of the protein component of plaques and aggregates related to pathological conditions |
| 06/21/2011 | CA2297408C Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
| 06/21/2011 | CA2280791C Immunological detection of prions |
| 06/21/2011 | CA2258735C Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus |
| 06/21/2011 | CA2177734C Construction of pasteurella heamolytica vaccines |
| 06/21/2011 | CA2171336C Recombinant il4 antibodies useful in treatment of il4 mediated disorders |
| 06/16/2011 | WO2011072263A1 Pcsk9 antagonists |
| 06/16/2011 | WO2011072205A2 Genetic markers indicative of a cancer patient response to trastuzumab (herceptin) |
| 06/16/2011 | WO2011072132A1 Methods of treating inflammatory conditions |
| 06/16/2011 | WO2011072124A1 Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| 06/16/2011 | WO2011072114A1 Dock-and-lock (dnl) complexes for delivery of interference rna |
| 06/16/2011 | WO2011071916A2 Sr-bi as a predictor of human female infertility and responsiveness to treatment |
| 06/16/2011 | WO2011071883A1 Anti-inflammatory antibodies and uses therefor |
| 06/16/2011 | WO2011071871A1 Methods for enhancing anti-tumor antibody therapy |
| 06/16/2011 | WO2011071783A1 Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof |
| 06/16/2011 | WO2011071577A1 Anti-vegf-c antibodies and methods using same |
| 06/16/2011 | WO2011071574A2 Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
| 06/16/2011 | WO2011071404A1 Immunogens, compositions and uses thereof, method for preparing same |
| 06/16/2011 | WO2011071134A1 Prophylactic composition for influenza infection |
| 06/16/2011 | WO2011071099A1 Anticancer anti-mortalin peptide antibodies |
| 06/16/2011 | WO2011071059A1 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance |
| 06/16/2011 | WO2011071039A1 Identification of hla-dr4 epitope and use for treatment of arthritis |
| 06/16/2011 | WO2011070443A1 Monoclonal antibodies that bind b7h6 and uses thereof |
| 06/16/2011 | WO2011070339A1 Method of treating disease |
| 06/16/2011 | WO2011070172A1 Anti-inflammatory agents directed against citrullinated epitopes |
| 06/16/2011 | WO2011070088A1 Anti-c4.4a antibodies and uses thereof |
| 06/16/2011 | WO2011070045A1 Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
| 06/16/2011 | WO2011069799A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069798A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069797A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069796A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069795A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069794A1 Neutralizing prolactin receptor antibodies and their therapeutic use |
| 06/16/2011 | WO2011069562A1 Human papillomavirus like structures produced in a non-fermentative system based on insect larva |
| 06/16/2011 | WO2011069527A1 Treatment scheme for idd and other automimmune diseases |
| 06/16/2011 | WO2011069408A1 Polypeptide immunogen, preparation method and use thereof |
| 06/16/2011 | WO2011047011A3 Treatment and diagnosis of inflammatory disorders |
| 06/16/2011 | WO2011043830A3 Methods, agents and peptides for inducing an innate immune response in hiv vaccination |
| 06/16/2011 | WO2011031063A9 Composition for preventing or treating metabolic disorders, containing the anti-4-1bb antibody |
| 06/16/2011 | WO2011025128A4 Method for treating th17 inflammatory disease through inhibition of vascular endothelial growth factor receptors and pharmaceutical composition therefor |
| 06/16/2011 | WO2011022462A3 Neural regeneration |
| 06/16/2011 | WO2011020095A3 Compositions and methods of treating inflammation |
| 06/16/2011 | WO2011019932A9 Compositions and methods for the therapy and diagnosis of influenza |
| 06/16/2011 | WO2011017442A3 Anti-rsv immunogens and methods of immunization |
| 06/16/2011 | WO2011017162A9 Methods for enhancing antigen-specific immune responses |
| 06/16/2011 | WO2010132561A3 New human rotavirus strains and vaccines |
| 06/16/2011 | US20110145941 Antibodies and derivatives thereof |
| 06/16/2011 | US20110144309 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 06/16/2011 | US20110144015 Methods for treating muscle diseases and disorders |
| 06/16/2011 | US20110143995 Novel anti-allergic agents |
| 06/16/2011 | US20110143431 Method Of Preparing An Undifferentiated Cell |
| 06/16/2011 | US20110143424 Recombinant influenza viruses for vaccines and gene therapy |
| 06/16/2011 | US20110143422 Recovery of recombinant human parainfluenza virus type 2 (hypiv2) from cdna and use of recombinant hpiv2 in immunogenic compositions and as vectors to elicit immune responses against piv and other human pathogens |
| 06/16/2011 | US20110142934 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season |
| 06/16/2011 | US20110142926 Nanoparticles for protein drug delivery |
| 06/16/2011 | US20110142923 Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye |
| 06/16/2011 | US20110142916 Adjuvants for Use in Vaccination |
| 06/16/2011 | US20110142915 Compositions and methods for inhibition of vegf |
| 06/16/2011 | US20110142912 Non-specific immunostimulating agents |
| 06/16/2011 | US20110142911 HIV epitopes and pharmaceutical composition containing same |
| 06/16/2011 | US20110142887 Methods and compositions for liquidation of tumors |
| 06/16/2011 | US20110142882 Control of blood flow in skin, subcutaneous tissue and muscle by botulinum toxin, snare protein mediating substances, and alpha adrenergic agents by either injection of transdermal delivery systems |
| 06/16/2011 | US20110142881 Transcutaneous delivery of therapeutic agents |
| 06/16/2011 | US20110142880 Lentivirus-based immunogenic vectors |
| 06/16/2011 | US20110142879 Infectious clones |
| 06/16/2011 | US20110142878 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| 06/16/2011 | US20110142877 Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents |
| 06/16/2011 | US20110142876 Conjugated vi saccharides |
| 06/16/2011 | US20110142874 Compositions, Methods, and Kits for Eliciting an Immune Response |
| 06/16/2011 | US20110142873 Bioactive purified hspe7 compositions |
| 06/16/2011 | US20110142872 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/16/2011 | US20110142871 Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| 06/16/2011 | US20110142870 Bacillus anthracis antigens, vaccine compositions, and related methods |
| 06/16/2011 | US20110142869 Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine |
| 06/16/2011 | US20110142868 Peptidylarginine Deiminase (PAD) Inhibitors |
| 06/16/2011 | US20110142867 Immunotherapeutic methods and systems |
| 06/16/2011 | US20110142866 Peptide analogues and conjugates thereof |
| 06/16/2011 | US20110142865 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142864 Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules |
| 06/16/2011 | US20110142863 Flow through purification processes for large biomolecules |
| 06/16/2011 | US20110142862 Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications |
| 06/16/2011 | US20110142861 Depletion of cd103 expressing cells for treatment of disorders |
| 06/16/2011 | US20110142860 Depletion of CD103 Expressing Cells for Treatment of Disorders |
| 06/16/2011 | US20110142859 Antibodies and immunoconjugates and uses therefor |
| 06/16/2011 | US20110142858 Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| 06/16/2011 | US20110142857 Methods of altering peripheral b cell populations and uses thereof |
| 06/16/2011 | US20110142856 Compound containing basic group and use thereof |
| 06/16/2011 | US20110142855 Compounds Having CRTH2 Antagonist Activity |
| 06/16/2011 | US20110142854 Compositions and methods for inhibition of retroviruses |
| 06/16/2011 | US20110142853 Engineered Anti-IL-23p19 Antibodies |
| 06/16/2011 | US20110142852 Multispecific antibodies |
| 06/16/2011 | US20110142851 IL6 Immunotherapeutics |